Oragenics Inc (NYSEAMERICAN:OGEN) traded up 11.8% during trading on Monday . The company traded as high as $0.60 and last traded at $0.57, 2,267,980 shares changed hands during mid-day trading. An increase of 85% from the average session volume of 1,225,374 shares. The stock had previously closed at $0.51.
Separately, HC Wainwright set a $2.00 target price on Oragenics and gave the company a “buy” rating in a research report on Friday, August 16th.
Oragenics (NYSEAMERICAN:OGEN) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03).
Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Featured Story: What are defining characteristics of a correction?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.